JP Patent

JP2022545568A — Ｊａｋ阻害剤による白斑の局所治療

Assigned to Incyte Corp · Expires 2022-10-27 · 4y expired

What this patent protects

本開示は、ルキソリチニブまたはその薬学的に許容される塩を使用する白斑の局所治療に関する。

USPTO Abstract

本開示は、ルキソリチニブまたはその薬学的に許容される塩を使用する白斑の局所治療に関する。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: JP2022545568A
Jurisdiction: JP
Classification: —
Expires: 2022-10-27
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.